CARLSBAD, CA, Carlsmed, an AI-enabled personalized surgery Medtech company, announced a $52.5M Series C funding round co-led by B Capital and U.S. Venture Partners.
Carlsmed, an AI-enabled personalized surgery Medtech company, announced a $52.5M Series C funding round co-led by B Capital and U.S. Venture Partners. These proceeds will be used to accelerate the commercialization of the aprevo® personalized spine surgery platform for lumbar fusion procedures and the development of aprevo® for cervical fusions, which will launch in 2025.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
